Spots Global Cancer Trial Database for vegf
Every month we try and update this database with for vegf cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | NCT00280007 | Hepatocellular ... | bevacizumab | 18 Years - 85 Years | Medical University of Vienna | |
| This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 | NCT03292783 | Advanced Solid ... | NOV1501 (ABL001... | 19 Years - | ABL Bio, Inc. | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00056199 | Hippel-Lindau D... | EYE001 | - | National Institutes of Health Clinical Center (CC) | |
| Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | NCT05675033 | Lung Adenocarci... Stage IV Non-sm... PD-1 Inhibitor VEGF | Serplulimab and... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | NCT00460317 | Non-Small Cell ... | AMG 706 placebo paclitaxel carboplatin | 18 Years - | Amgen | |
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression | NCT00676793 | Breast Cancer | Polyphenon E | 21 Years - 75 Years | Louisiana State University Health Sciences Center Shreveport | |
| Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer | NCT01972373 | Rectal Cancer | Bevacizumab-IRD... NIR fluorescenc... | 18 Years - | University Medical Center Groningen | |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | NCT00322400 | Locally Recurre... | Docetaxel Paclitaxel AMG 706 | 18 Years - | Amgen | |
| A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma | NCT04736810 | Nasopharyngeal ... | AK105 Cisplatin Gemcitabine Anlotinib hydro... | 18 Years - 75 Years | Akeso | |
| Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | NCT06133062 | Hepatocellular ... | Atezolizumab Bevacizumab Proton radiothe... | 18 Years - | Chang Gung Memorial Hospital | |
| Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab | NCT04770376 | Ovarian Cancer | Observational s... | 18 Years - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00089765 | Von Hippel-Lind... | Ranibizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| VEGF Early Imaging for Breast Cancer | NCT00991978 | Breast Cancer | 89Zr-bevacizuma... | 18 Years - | University Medical Center Groningen | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay | NCT04240600 | Acute Myeloid L... | Experimental gr... Control group | 18 Years - 60 Years | Hospital General de Mexico | |
| The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC) | NCT02839668 | Breast Cancer | Lidocaine Sevoflurane TIVA-TCI Acetaminophen Tramadol Neostigmine Atropine BIS | 18 Years - 80 Years | Iuliu Hatieganu University of Medicine and Pharmacy | |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | NCT01956669 | Solid Tumours | Pazopanib | 1 Year - 18 Years | Novartis | |
| PTC299 for Treatment of Advanced Cancer | NCT00704821 | Advanced Cancer | PTC299 Docetaxel | 18 Years - | PTC Therapeutics | |
| PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | NCT00508586 | Metastatic Brea... | PTC299 | 18 Years - | PTC Therapeutics | |
| Angiogenic Factor Expression During Fractionated Irradiation | NCT02072720 | Primary Esophag... | Bevacizumab | 18 Years - | Amsterdam UMC, location VUmc | |
| Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) | NCT00095706 | Breast Cancer | Bevacizumab (dr... | 18 Years - 75 Years | Translational Oncology Research International | |
| Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients | NCT00985036 | Glioma Meningioma | Blood test | - | Marquette General Health System | |
| Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients | NCT00985036 | Glioma Meningioma | Blood test | - | Marquette General Health System | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer | NCT01508572 | Breast Cancer | bevacizumab-IRD... | 18 Years - | University Medical Center Groningen | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | NCT00942877 | Sarcoma, Alveol... | AZD2171 | - 16 Years | National Institutes of Health Clinical Center (CC) | |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer | NCT03251378 | Advanced Solid ... Metastatic Colo... Metastatic Brea... Triple Negative... HER2-negative B... Hormone Recepto... Rectal Cancer | Fruquintinib (H... | 18 Years - | Hutchmed | |
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | NCT04444167 | Hepatocellular ... | AK104 Lenvatinib | 18 Years - 75 Years | Akeso | |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | NCT01956669 | Solid Tumours | Pazopanib | 1 Year - 18 Years | Novartis | |
| PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | NCT00508586 | Metastatic Brea... | PTC299 | 18 Years - | PTC Therapeutics | |
| VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer | NCT01508572 | Breast Cancer | bevacizumab-IRD... | 18 Years - | University Medical Center Groningen | |
| A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | NCT03503604 | Solid Tumors | hPV19 mAb hPV19 mAb 5-Fluorouracil Oxaliplatin Leucovorin Paclitaxel Carboplatin Gemcitabine Carboplatin Irinotecan | 18 Years - 75 Years | SuZhou Stainwei Biotech Inc. | |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| SU5416 and Carboplatin to Treat Ovarian Cancer | NCT00006155 | Fallopian Tube ... Ovarian Cancer Peritoneal Neop... | SU5416 and carb... | - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | NCT01379534 | Solid Tumors an... Endometrial Can... Second-line Tre... VEGF | TKI258 | 18 Years - | Novartis | |
| Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients | NCT01136083 | Non-small-cell ... | Exercise traini... Usual care | 40 Years - 75 Years | National Taiwan University Hospital | |
| Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | NCT01621568 | Thymoma Thymus Neoplasm... | Sunitinib Sunitinib | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer | NCT01551641 | Esophageal Canc... | chemoradiothera... thalidomide without thalido... | 20 Years - 80 Years | Changzhou No.2 People's Hospital | |
| Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | NCT06339424 | Hepatocellular ... | Atezolizumab Bevacizumab Photon radiothe... | 18 Years - | Chang Gung Memorial Hospital | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer | NCT01508572 | Breast Cancer | bevacizumab-IRD... | 18 Years - | University Medical Center Groningen | |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | NCT04579757 | Metastatic Soli... Colorectal Canc... Neuroendocrine ... Small Cell Lung... Gastric Cancer Soft Tissue Sar... Anaplastic Thyr... | Surufatinib and... Surufatinib and... | 18 Years - | Hutchmed | |
| A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases | NCT01120288 | Neoplasms Liver Metastase... | EZN-2968 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol | NCT00392548 | Glioblastoma | 18 Years - | Tel-Aviv Sourasky Medical Center | ||
| Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | NCT06339424 | Hepatocellular ... | Atezolizumab Bevacizumab Photon radiothe... | 18 Years - | Chang Gung Memorial Hospital | |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | NCT00460317 | Non-Small Cell ... | AMG 706 placebo paclitaxel carboplatin | 18 Years - | Amgen | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | NCT04444167 | Hepatocellular ... | AK104 Lenvatinib | 18 Years - 75 Years | Akeso | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | NCT03503604 | Solid Tumors | hPV19 mAb hPV19 mAb 5-Fluorouracil Oxaliplatin Leucovorin Paclitaxel Carboplatin Gemcitabine Carboplatin Irinotecan | 18 Years - 75 Years | SuZhou Stainwei Biotech Inc. | |
| Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | NCT01445509 | Solid Tumors | Bevacizumab Dasatinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| SU5416 and Carboplatin to Treat Ovarian Cancer | NCT00006155 | Fallopian Tube ... Ovarian Cancer Peritoneal Neop... | SU5416 and carb... | - | National Institutes of Health Clinical Center (CC) | |
| Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib | NCT03129724 | Kidney Neoplasm... | 18 Years - | University Hospital, Strasbourg, France | ||
| Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | NCT06133062 | Hepatocellular ... | Atezolizumab Bevacizumab Proton radiothe... | 18 Years - | Chang Gung Memorial Hospital | |
| A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | NCT01379534 | Solid Tumors an... Endometrial Can... Second-line Tre... VEGF | TKI258 | 18 Years - | Novartis | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Open-Label Surufatinib in European Patients With NET | NCT04579679 | Neuroendocrine ... Neuroendocrine ... Small Intestina... | Surufatinib | 18 Years - | Hutchmed | |
| The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC) | NCT02839668 | Breast Cancer | Lidocaine Sevoflurane TIVA-TCI Acetaminophen Tramadol Neostigmine Atropine BIS | 18 Years - 80 Years | Iuliu Hatieganu University of Medicine and Pharmacy | |
| An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma | NCT05217147 | Larynx Cancer Larynx Carcinom... | Obtaining blood... | - | Hacettepe University | |
| A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | NCT03136653 | Multiple Myelom... | MP0250 plus BOR... | 18 Years - | Molecular Partners AG | |
| Trisenox® in Women With Metastatic Endometrial Cancer | NCT01184053 | Endometrial Car... | Arsenic trioxid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients | NCT03114826 | Polymorphism VEGF Renal Carcinoma Renal Transplan... | To study the po... | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| AZD2171 to Treat Prostate Cancer | NCT00436956 | Prostate Cancer | Magnetic Resona... AZD2171 Prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma | NCT05217147 | Larynx Cancer Larynx Carcinom... | Obtaining blood... | - | Hacettepe University | |
| Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer | NCT01015625 | Synchronous Met... Circulating Tum... | Surgery Surgery on Dema... | 18 Years - | Austrian Breast & Colorectal Cancer Study Group | |
| Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer | NCT00016549 | Breast Cancer | Bevacizumab | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
